Business Wire

EUROSETS

17.7.2024 11:13:26 CEST | Business Wire | Press release

Share
Eurosets: Newborn baby saved from acute bronchiolitis in Martinique by Colibri third-generation life-support device

The baby was affected by a viral infection, leaving him unable to breathe. Thanks to a state-of-the-art device, used for the first time in the world in the Caribbean, the medical-surgical team was able to save the infant.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716825866/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Colibrì, the lightest life-saving device that replaces the function of the heart and lungs (Photo: Eurosets)

The Colibri (hummingbird), one of the national symbols of Martinique, is also the name of an innovative, next-generation ECMO system, designed and manufactured by Eurosets, an Italian company based in the biomedical district of Medolla (MO), which enabled the medical-surgical team at Martinique University Hospital to save the life of a one-and-a-half-month-old child suffering from acute bronchiolitis.
The baby was born in Guadeloupe and weighed just 5kg. He was unable to breathe independently due to the viral infection, which subsequently led to heart failure. The infant was immediately transferred to the CHU de Martinique (CHUM), the only French hospital in the Caribbean with a third-level pediatric intensive care unit but, due the child's unstable condition, it was impossible to move him.
Following first-rate coordination with the neonatal intensive care unit at Guadeloupe University Hospital, the Martinique team from the UMAC (Unité Mobile d'Assistance Circulatoire) was able to travel to the neighboring island and connect the new ECMO system in the jugulo-carotid position to the newborn, allowing the infant to be transferred safely by helicopter.
The procedure was a success thanks to the seamless cooperation between Dr Xavier Beretta-Piccoli, pediatric intensive care specialist, and Dr Fabio Cuttone, head of pediatric cardiac surgery at the CHUM.
This intervention marked the world's first installation of a third-generation transportable device entirely designed and adapted for infants and children. The UMAC 972, consisting of a medical (intensive care specialist, cardiac surgeon) and paramedical (perfusionist) team, a pioneer in mobile circulatory assistance in the Caribbean archipelago and unique in terms of know-how and experience, played a vital role in the success of this medical treatment.
The infant was admitted to the CHUM pediatric intensive care unit. He received care and was attached to Colibri for five days until his lungs and heart functioned normally. Subsequently, having fully recovered from his bronchiolitis, the child was discharged from hospital and returned to Guadeloupe after 15 days in hospital. He will have to be monitored periodically, like all babies who have been in intensive care. He is now out of danger.

This ground-breaking treatment, the result of cooperation between the Martinique University Hospital, Eurosets, the CTM (Collectivité Territoriale de la Martinique) and European funding from React-UE (Recovery assistance for cohesion and the territories of Europe), finally provides the children of the Caribbean archipelago with a life-saving strategy at the forefront of technology.
Colibri is the world's lightest life-saving device capable of temporarily replacing cardiac and pulmonary functions. It is the only third-generation transportable system entirely designed and adapted to newborns and children.
In addition to adult patients, the device can be used on pediatric or even neonatal patients thanks to a dedicated centrifugal pump. The technology is suitable for use in a variety of therapeutic applications, including extracorporeal cardiopulmonary resuscitation (E-CPR) in cardiac arrest, extracorporeal membrane oxygenation (ECMO) and mechanical circulatory support (MCS).

Equipped with a centrifugal pump with magnetic levitation and a device capable of artificially oxygenating the blood, as well as offering excellent ergonomics, the Colibri is a high-performance circulatory assistance system, ideal in all situations in which intra- and extra-hospital transportability are crucial, including the most extreme rescue operations, such as airborne medical evacuations (by helicopter, passenger airline or military aircraft), scenarios that are common in the Caribbean region.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be crossreferenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716825866/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye